<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45258">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01948726</url>
  </required_header>
  <id_info>
    <org_study_id>ARO 2013-04</org_study_id>
    <nct_id>NCT01948726</nct_id>
  </id_info>
  <brief_title>Hypofractionation With Simultaneous Integrated Boost for Early Breast Cancer</brief_title>
  <official_title>Multicenter Phase-II-Trial of Evaluation of Acute Toxicity in Hypofractionation With Simultaneous Integrated Boost for Early Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Schleswig-Holstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Luebeck</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Schleswig-Holstein</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypofractionation with simultaneous integrated boost has been investigated in a few trials
      and appears to be safe and feasible with less lung toxicity in smaller studies.

      Investigators initiated this multicenter phase II prospective trial to analyse acute
      toxicity of hypofractionation with simultaneous integrated boost in patients with early
      breast cancer under the hypothesis that the ratio of patients with acute radiogenic toxicity
      Grad II according NCI-CTCAE amounts maximum 20%.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypofractionated radiotherapy of the breast 16 × 2.50 Gy with simultaneous integrated boost
      to the tumor bed (total dose within the boost volume 16 × 3.00 Gy).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Acute Toxicity</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Acute skin radiogenic toxicity grade II or higher according to NCI-CTCAE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility</measure>
    <time_frame>22-29 days (16 fractions)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Dose constraints Dmedian lung	 &lt; 10 Gy; Dmedian heart &lt; 5 Gy, Dmax ≤ 40 Gy; Dmedian anterior branch of the left coronary artery (LAD, RIVA) &lt; 15 Gy, Dmax ≤ 40 Gy; Dmedian contralateral breast &lt; 3 Gy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>0 to 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>All dimensions of NCI-CTCAE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>0 to 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>EORTC QLQ-C30, -BR23</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance</measure>
    <time_frame>0 to 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>ECOG</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Skin toxicity (Cosmetic results)</measure>
    <time_frame>0 to 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>NCI-CTCAE</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Breast Cancer After Breast Conserving Surgery Indicating Postoperative Radiotherapy With Boost</condition>
  <arm_group>
    <arm_group_label>Hypofractionation with SIB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionation with simultaneous integrated boost</intervention_name>
    <arm_group_label>Hypofractionation with SIB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histopathologically confirmed breast cancer operated by breast conserving surgery
             with clear margins

          -  Indication to adjuvant radiotherapy including boost radiotherapy

          -  Clearly identified primary tumor region preferably by radiopaque clips

          -  Primary wound healing after breast conserving therapy without signs of infection

          -  Pre- and/or postoperative chemotherapy and endocrine therapy were permitted when
             indicated

          -  Written informed consent

        Exclusion Criteria:

          -  Patients operated by mastectomy

          -  No indication for boost radiation

          -  Resection margins positive for disease or insufficient identification of the boost
             volume

          -  Indication for radiotherapy of the regional lymph nodes

          -  History of prior breast or thoracic radiotherapy

          -  Extended postoperative seroma at the beginning of radiotherapy

          -  Psychiatric disorders or psychological disabilities thought to adversely affect
             treatment compliance

          -  Pregnant or lactating patients and woman of child bearing potential, who lacked
             effective contraception
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juergen Dunst, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>University Medical Center Schleswig-Holstein (UKSH)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juergen Dunst, Prof.</last_name>
    <phone>0049/431/597/3011</phone>
    <email>Juergen.Dunst@uk-sh.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kathrin Dellas, MD</last_name>
    <phone>0049/431/597/3011</phone>
    <email>Kathrin.Dellas@uksh.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charité University Medical Center Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ursula Höller, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ursula Höller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Buchholz</name>
      <address>
        <city>Buchholz</city>
        <zip>21244</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Andreas, MD</last_name>
    </contact>
    <investigator>
      <last_name>Peter Andreas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum des Landkreises Deggendorf Mammazentrum</name>
      <address>
        <city>Deggendorf</city>
        <zip>94469</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Klug, MD</last_name>
    </contact>
    <investigator>
      <last_name>Michael Klug, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Praxis für Strahlentherapie am Krankenhaus Dresden-Friedrichstadt</name>
      <address>
        <city>Dresden</city>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joerg Zimmer, MD</last_name>
    </contact>
    <investigator>
      <last_name>Joerg Zimmer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Malteser St. Franziskus-Hospital</name>
      <address>
        <city>Flensburg</city>
        <zip>24939</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hans-Juergen Brodersen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Hans-Juergen Brodersen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onkologischer Schwerpunkt (OSP) Goeppingen</name>
      <address>
        <city>Goeppingen</city>
        <zip>73006</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Esther Herrmann, MD</last_name>
    </contact>
    <investigator>
      <last_name>Esther Herrmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Strahlenzentrum Hamburg Nord</name>
      <address>
        <city>Hamburg</city>
        <zip>22419</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabian Fehlhauer, MD</last_name>
    </contact>
    <investigator>
      <last_name>Fabian Fehlhauer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radiologie and Radioonkologie</name>
      <address>
        <city>Hamburg</city>
        <zip>22767</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Würschmidt, MD</last_name>
    </contact>
    <investigator>
      <last_name>Florian Würschmidt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Schleswig-Holstein (UKSH), Department of Radiotherapy, Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juergen Dunst, Prof.</last_name>
      <phone>0049/431/597/3011</phone>
      <email>Juergen.Dunst@uk-sh.de</email>
    </contact>
    <contact_backup>
      <last_name>Kathrin Dellas, MD</last_name>
      <phone>0049/431/597/3011</phone>
      <email>Kathrin.Dellas@uksh.de</email>
    </contact_backup>
    <investigator>
      <last_name>Juergen Dunst, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kirsten Eilf, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kathrin Dellas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MGZ Luebeck im Hochschulstadtteil</name>
      <address>
        <city>Luebeck</city>
        <zip>23562</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bernd Brandenburg, MD</last_name>
    </contact>
    <investigator>
      <last_name>Bernd Brandenburg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Schleswig-Holstein (UKSH), Department of Radiotherapy, Campus Luebeck</name>
      <address>
        <city>Luebeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dirk Rades, Prof.</last_name>
      <phone>0049/451/5006661</phone>
    </contact>
    <investigator>
      <last_name>Dirk Rades, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Staedtisches Klinikum Lueneburg</name>
      <address>
        <city>Lueneburg</city>
        <zip>21339</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Dinges, MD</last_name>
    </contact>
    <investigator>
      <last_name>Stefan Dinges, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Mainz, Department of Radiotherapy</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heinz Schmidberger, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Heinz Schmidberger, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Rechts der Isar Department of Radiotherapy Muenchen</name>
      <address>
        <city>Muenchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Molls, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Michael Molls, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radiology Pinneberg</name>
      <address>
        <city>Pinneberg</city>
        <zip>25421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Meinolf Marx, MD</last_name>
    </contact>
    <investigator>
      <last_name>Meinolf Marx, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helios Kliniken Schwerin</name>
      <address>
        <city>Schwerin</city>
        <zip>19049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heinrich Annweiler, MD</last_name>
    </contact>
    <investigator>
      <last_name>Heinrich Annweiler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johanniter-Krankenhaus Genthin-Stendal</name>
      <address>
        <city>Stendal</city>
        <zip>39576</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>E. Weinstrauch, MD</last_name>
    </contact>
    <investigator>
      <last_name>E. Weinstrauch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MVZ Klinikum Straubing GmbH</name>
      <address>
        <city>Straubing</city>
        <zip>94315</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthias Hipp, MD</last_name>
    </contact>
    <investigator>
      <last_name>Matthias Hipp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heinrich-Braun-Klinikum Zwickau</name>
      <address>
        <city>Zwickau</city>
        <zip>08060</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Boicev, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alexander Boicev, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 7, 2014</lastchanged_date>
  <firstreceived_date>August 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Schleswig-Holstein</investigator_affiliation>
    <investigator_full_name>Juergen Dunst, Prof.</investigator_full_name>
    <investigator_title>Prof. Dr. med. Juergen Dunst</investigator_title>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Hypofractionation</keyword>
  <keyword>Simultaneous integrated boost</keyword>
  <keyword>Toxicity</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
